Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Share-based Compensation (2016 - 2025)

Abeona Therapeutics (ABEO) has 15 years of Share-based Compensation data on record, last reported at $2.7 million in Q3 2025.

  • For Q3 2025, Share-based Compensation rose 49.06% year-over-year to $2.7 million; the TTM value through Sep 2025 reached $10.2 million, up 64.46%, while the annual FY2024 figure was $6.6 million, 39.01% up from the prior year.
  • Share-based Compensation reached $2.7 million in Q3 2025 per ABEO's latest filing, down from $2.8 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $5.1 million in Q4 2021 and bottomed at $632000.0 in Q3 2022.
  • Average Share-based Compensation over 5 years is $1.8 million, with a median of $1.6 million recorded in 2023.
  • Peak YoY movement for Share-based Compensation: surged 189.21% in 2021, then plummeted 83.73% in 2022.
  • A 5-year view of Share-based Compensation shows it stood at $5.1 million in 2021, then tumbled by 83.73% to $833000.0 in 2022, then surged by 81.75% to $1.5 million in 2023, then rose by 29.13% to $2.0 million in 2024, then soared by 37.54% to $2.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Share-based Compensation were $2.7 million in Q3 2025, $2.8 million in Q2 2025, and $2.7 million in Q1 2025.